Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines. It arises from the chromaffin cells of the adrenal medulla. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor. Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen. Other growth patterns including trabecular pattern may also be present.
Biomarker and diagnostic research for adrenal gland pheochromocytoma has been reported in the published literature.
53 clinical trials registered, 25 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 17 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06523582](https://clinicaltrials.gov/study/NCT06523582) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Common questions about adrenal gland pheochromocytoma
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients |
— |
Universidad Nacional Autonoma de Mexico |
RECRUITING |
[NCT06444607](https://clinicaltrials.gov/study/NCT06444607) | Hereditary Pheochromocytoma Assessment of Tumour Immunologies | — | Radboud University Medical Center | RECRUITING |
[NCT03344016](https://clinicaltrials.gov/study/NCT03344016) | Multicenter Pheochromocytoma and Paraganglioma Evaluation | NA | Felix Beuschlein | RECRUITING |
[NCT07288931](https://clinicaltrials.gov/study/NCT07288931) | Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma | NA | Peking Union Medical College Hospital | RECRUITING |
[NCT06683846](https://clinicaltrials.gov/study/NCT06683846) | Ivonescimab in the Treatment of Multiple Advanced Tumors | PHASE2 | Fudan University | RECRUITING |
141 publications have been identified in PubMed for adrenal gland pheochromocytoma. Research spans Review / Meta-Analysis (51%), Diagnostic / Biomarker (11%), and Basic Science / Preclinical (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 63 | 51% |
Testing and diagnosis research | 14 | 11% |
Laboratory research | 14 | 11% |
Patient case studies | 12 | 10% |
Disease patterns and progression | 12 | 10% |
Clinical study results | 5 | 4% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Mahmood E (2026). [PMID: 30969728](https://pubmed.ncbi.nlm.nih.gov/30969728/). *Unknown Journal*. [Case Report / Case Series]
Halperin R (2026). [PMID: 41783997](https://pubmed.ncbi.nlm.nih.gov/41783997/). *Eur J Endocrinol*. [Epidemiology / Natural History]
Decmann A (2026). [PMID: 41532570](https://pubmed.ncbi.nlm.nih.gov/41532570/). *Endocr Relat Cancer*. [Review / Meta-Analysis]
Park MJ (2026). [PMID: 41781348](https://pubmed.ncbi.nlm.nih.gov/41781348/). *J Intern Med*. [Epidemiology / Natural History]
Alkaissi H (2026). [PMID: 42067273](https://pubmed.ncbi.nlm.nih.gov/42067273/). *Endocrinol Metab Clin North Am*. [Review / Meta-Analysis]
Jena S (2026). [PMID: 41736347](https://pubmed.ncbi.nlm.nih.gov/41736347/). *J Pak Med Assoc*. [Review / Meta-Analysis]
Berber E (2026). [PMID: 42104782](https://pubmed.ncbi.nlm.nih.gov/42104782/). *J Laparoendosc Adv Surg Tech A*. [Other]
Bridwell RE (2026). [PMID: 41656028](https://pubmed.ncbi.nlm.nih.gov/41656028/). *Endocrinol Metab Clin North Am*. [Review / Meta-Analysis]
Alkaissi H (2026). [PMID: 41043588](https://pubmed.ncbi.nlm.nih.gov/41043588/). *Endocr Pract*. [Epidemiology / Natural History]
Phadte A (2026). [PMID: 41956124](https://pubmed.ncbi.nlm.nih.gov/41956124/). *Horm Metab Res*. [Review / Meta-Analysis]
AI-curated news mentioning adrenal gland pheochromocytoma
Updated Sep 15, 2026
A recent case report highlights a rare instance of pheochromocytoma presenting as acute coronary syndrome, leading to cardiogenic shock. This case underscores the importance of considering rare diseases in differential diagnoses.
Recent research highlights belzutifan, a hypoxia-inducible factor 2-alpha inhibitor, as a potential treatment for patients with advanced pheochromocytoma and paraganglioma. This study contributes to the understanding of targeted therapies for these rare tumors.
New research identifies biomarkers associated with metastatic disease in pheochromocytoma and paraganglioma, potentially aiding in diagnosis and treatment strategies. This study enhances understanding of these rare tumors and their progression.